- Genius expands its Phase Ib / IIa clinical trial as a leading indicator for the treatment of patients with advanced hepatocellular carcinoma
- Funding led by Flerie Invest and Dr. Ted Fjällman joins Genius Board of Directors
Plymouth Meeting, Pa., March 24, 2022 / PRNewswire / – Genital TherapyClinical Phase Biotherapeutics, a company that focuses on personal immunosuppressive therapy targeting tumor nevantigan, announced today that it has secured 17 17 million in funding for the A2 series. The funding was led by Flerie Invest, which includes all existing Series A investors, including Santi Ventures, Korean Investment Partners (KIP) -Global Biofund, and INOVIO Pharmaceuticals (NASDAQ: INO). Together with the funding, Dr. Ted Fugelman, a friend, Fleury Capital joined the board of directors of Genius.
“Genius personal immunity therapy reveals interesting clinical data in liver cancer patients and the behavior differs significantly from the competition,” commented Dr. Fajman. “Fleury is pleased to work with a large set of team and investors to accelerate the clinical development of this innovative platform technology.”
The money will be used to develop the company’s GT-30 Phase Ib / IIa clinical trials. GT-30 evaluates the Genius personal cancer vaccine, GNOS-PV02, for the treatment of patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. GNOS-PV02, a tumor-specific DNA plasmid-based product designed and produced for each patient based on their specific tumor mutations (neonatigens), is identified with each patient’s tumor configuration. In the trial, GNOS-PV02 was combined with the DNA-encoded cytokine IL-12 (INO-9012) and PD-1 post-inhibitor (pembrolizamab). Genius will increase the number of treatment patients from 24 to 36 patients. In addition, the money will give a new impetus to pipeline development, and continue the company’s operations.
“We are pleased to welcome Ted to the Board of Directors and Flerie Invest in our Investors Syndicate. We are promoting our potentially mutable personalized cancer treatment. ” Dr. Naranjan Y. Sardesai, Founder and CEO of Genius Therapy said. “The funding of the Series A2 will enable us to expand our existing pipeline using our GT-EPIC ™ platform directness and invest in this early differentiated breakthrough in this treatment of liver cancer type treatment. We have already reported tumor reduction by more than half. Patients and RECIST 1.1 treated three-part reactions in the first 12 patients and a similar trend is seen in the next 12 patients. We look forward to reporting data continuity and key phase effects data. “
For more information about the company and its leadership team, visit www.geneostx.com
About the treatment of genital warts
At Genius Therapy, we believe that personalized therapy is the future of cancer treatment. Our passion is to create personalized therapies to unleash a very strong force against cancer – the patient’s own immune system. Our approach using our GT-EPIC ™ platform is to target specific new antigens (abnormal mutations produced by cancer cells) from individual patient tumors to create new and personalized treatments for cancer. We have an experienced management team with a track record of success in creating immune treatment based companies.
About liver cancer
Globally, liver cancer is the fourth most common cause of cancer-related deaths and the sixth largest annual cause. Liver cancer mortality in the United States increased 43% from 2000 to 2016 and 18% for advanced liver cancer with a 5-year survival rate, making it the second deadliest tumor after pancreatitis. HCC makes up the majority of early liver cancers.
About GT-EPIC ™ Platform:
Genius’ therapeutic property GT-EPIC ™ Neoantigen-Targeting Platform is based on the design and delivery of highly desirable synthetic DNA plasmids and their combinations for cancer immunity treatment. The GT-EPIC™ platform allows Genius to create exciting personalized treatments tailored to each patient’s specific tumor changes. The platform is designed to offer the following key benefits: the ability to drive strong and broad T cell immune responses, the ability to target an unprecedented number of neonates in a single formulation, and the rapid production transition time. Genius believes that these are the three key differences that the company and the oncology space will pass on to the next generation of personal immunity therapists.
About Fleury Investments:
Flerie Invest is a European biotech and pharma investor managing a portfolio of more than 20 companies in the United States, the United Kingdom, Sweden and other countries. Portfolio companies are engaged in a wide range of fields including amino oncology, metabolic diseases and biological development and production. The current investment focus is on drug development and tools for drug development. The company was founded in 2010 by Thomas Elderd, who is one of the five leading manufacturers of pharmaceutical contracts worldwide to coordinate and formulate Reform. Flerie Invest is based in Stockholm and London.
This press release contains some forward-looking statements related to our business, including our plans for the development of a personal immunotherapy treatment targeting tumor nevantigan for cancer, our expectations regarding our research and development program, including the planned Development and conduct and availability of clinical trials. And the timing of information from these courts, and the use of our capital resources. Actual events or outcomes may differ from the expectations presented here. There is no guarantee that any product candidate in the Genius Pipeline will be successfully created, produced or commercialized, that the final results of clinical trials will support the necessary regulatory approvals for marketing licensed products, or that Future information provided. Here will be proven accurate. Visionary statements are subject to release date only, and Genius has no obligation to update or review these statements, unless required by law.
See original content: https://www.prnewswire.com/news-releases/geneos-therapeutics-secures-17-million-in-series-a2-financing-to-advance-personalized-cancer-immunotherapy-platform-301509602. html
Source Genius Pharmacy, Inc.
Company Codes: NASDAQ-NMS: INO